Wide Ranks

AMPH

Amphastar Pharmaceuticals, Inc.

45.21

Top Statistics
Market Cap 2 B Forward PE 10.65 Revenue Growth 5.90 %
Current Ratio 3.43 Trailing PE 15.02 Earnings Growth -14.30 %
Profit Margins 21.80 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 9.58 Enterprise / Revenue 3.53 Price To Sales Trailing12 Months 3.00
Profitability
Profit Margins 21.80 % Operating Margins 29.83 %
Balance Sheet
Total Cash 250 M Total Cash Per Share 5.21 Total Debt 629 M
Total Debt To Equity 86.56 Current Ratio 3.43 Book Value Per Share 15.04
All Measures
Short Ratio 1142.00 % Message Board Id finmb_2003650 Shares Short Prior Month 4 M
Return On Equity 0.2385 City Rancho Cucamonga Uuid 287241c5-4a99-3b7c-9252-8dd38caf7256
Previous Close 44.22 First Trade Date Epoch Utc 1 B Book Value 15.04
Beta 0.8240 Total Debt 629 M Volume 439659
Price To Book 3.01 Fifty Two Week Low 36.56 Total Cash Per Share 5.21
Total Revenue 723 M Shares Short Previous Month Date 1 B Target Median Price 55.00
Audit Risk 5 Max Age 86400 Recommendation Mean 2.00
Sand P52 Week Change 0.3133 Operating Margins 29.83 % Target Mean Price 58.20
Net Income To Common 157 M Short Percent Of Float 0.1354 Implied Shares Outstanding 48 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 431480
Average Volume10days 431480 Total Cash 250 M Next Fiscal Year End 1 B
Revenue Per Share 14.94 Held Percent Insiders 0.2241 Ebitda Margins 36.85 %
Trailing PE 15.02 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 5 Regular Market Previous Close 44.22 Target Low Price 55.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 48.01 Open 44.23
Free Cashflow 8 M State CA Dividend Yield 0.00 %
Return On Assets 0.0867 Time Zone Short Name EST Board Risk 9
Trailing Eps 3.01 Day Low 44.23 Address1 11570 6th Street
Shares Outstanding 48 M Compensation Risk 5 Price Hint 2
Target High Price 66.00 Website https://www.amphastar.com 52 Week Change -0.1973
Average Volume 358776 Earnings Quarterly Growth -17.90 % Forward Eps 4.37
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 248.70 %
Is_sp_500 False Regular Market Day High 45.71 Profit Margins 21.80 %
Debt To Equity 86.56 Fifty Two Week High 65.92 Day High 45.71
Shares Short 4 M Regular Market Open 44.23 Industry Key drug-manufacturers-specialty-generic
Earnings Growth -14.30 % Enterprise To Revenue 3.53 Revenue Growth 5.90 %
Shares Percent Shares Out 0.0881 Operating Cashflow 208 M Currency USD
Time Zone Full Name America/New_York Market Cap 2 B Is_nasdaq_100 False
Zip 91730 Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic
Long Name Amphastar Pharmaceuticals, Inc. Overall Risk 6 Regular Market Day Low 44.23
Held Percent Institutions 0.7477 Current Price 45.21 Enterprise To Ebitda 9.58
Financial Currency USD Current Ratio 3.43 Gross Margins 52.98 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 5 Country United States
Float Shares 37 M Two Hundred Day Average 44.55 Governance Epoch Date 1 B
Enterprise Value 2 B Price To Sales Trailing12 Months 3.00 Forward PE 10.65
Regular Market Volume 439659 Ebitda 266 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.

It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures.

In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging.

Further, the company distributes recombinant human insulin APIs and porcine insulin API.

Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions.

The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.